Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

67 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Specification of the disease EBMT CLL

- 13/03/16 - 1 modulo, 11 itemgroups, 105 elementi, 1 linguaggio
Itemgroups: Initial Diagnosis, Pre-HSCT Treatment, Additional Treatment Pre-HSCT, Disease Status at HSCT, Disease Status at HSCT - Biological Risk Factor Assessment, Disease Status at HSCT - Haematological values, Disease Status at HSCT - Clinical data, Additional-Treatment Post-HSCT, Best Disease Response at 100 days post-HSCT, Best Disease Response at 100 days post-HSCT - Haematological values, Forms to be filled in
ODM derived from HSCT forms on http://www.ebmt.org/

Genereral information EBMT CLL

- 06/03/16 - 1 modulo, 3 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: Team, Patient, Disease
ODM derived from HSCT forms on http://www.ebmt.org/

Eligibility Leukemia NCT00275015

- 12/01/16 - 1 modulo, 1 ItemGroup, 11 elementi, 1 linguaggio
ItemGroup: Criteria
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00275015

Eligibility Chronic Lymphocytic Leukemia NCT00073489

- 10/01/16 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00073489

CLL Hospitalization BO17072 NCT00090051 - MRU-Hospitalization of Chronic lymphocytic leukemia NCT0090051

- 28/10/15 - 1 modulo, 1 ItemGroup, 4 elementi, 1 linguaggio
ItemGroup: Hospitalization
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Adverse Event BO17072 NCT00090051 - Adverse event or intercurrent illness Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 28/10/15 - 1 modulo, 2 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Adverse event, Adverse event treatments
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

Eligibility Chronic Lymphocytic Leukemia NCT01980875

- 30/08/15 - 1 modulo, 2 itemgroups, 21 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01980875

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial